Top

Published in:

01-10-2012

Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis

Authors: Nay M. Tun, Gina M. Villani

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2012

Abstract

Idiopathic thrombotic thrombocytopenic purpura (TTP) occurs primarily due to the formation of autoantibody against ADAMTS13, a specific von Willebrand factor-cleaving protease, resulting in low ADAMTS13 activity and subsequent accumulation of large vWF multimers, platelet aggregation and thrombus formation in the microvasculature of tissues. Limited clinical data suggest that the administration of anti-CD20 antibody (rituximab) may be useful in treating acute refractory or chronic relapsing idiopathic TTP. We carried out a systematic review with pooled data analysis using individual patient data to evaluate the efficacy of rituximab in these settings. Fifteen case series and 16 case reports comprising 100 patients were eligible for the study. Median age was 39 years. Male constituted 31 % and female 69 %. Complete remission was seen in 98 %, non-response in 2 % and relapse after complete remission in 9 %. For patients with complete remission, median follow-up was 13 months. Median platelet recovery from the first dose of rituximab was 14 days. ADAMTS13 inhibitor positivity and severe ADAMTS13 deficiency were highly predictive of the response to rituximab, implying that these can be useful markers in predicting response to rituximab in acute refractory or chronic relapsing idiopathic TTP.

Remuzzi G (1987) HUS and TTP: variable expression of a single entity. Kidney Int 32(2):292–308PubMedCrossRef

Ridolfi RL, Hutchins GM, Bell WR (1979) The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med 91(3):357–363PubMed

Bell MD, Barnhart JS Jr, Martin JM (1990) Thrombotic thrombocytopenic purpura causing sudden, unexpected death–a series of eight patients. J Forensic Sci 35(3):601–613PubMed

Podolsky SH, Zembowicz A, Schoen FJ, Benjamin RJ, Sonna LA (1999) Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med 123(10):937–940PubMed

Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347(8):589–600PubMedCrossRef

Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584PubMedCrossRef

Sadler JE (2008) Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112(1):11–18PubMedCrossRef

Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339(22):1585–1594PubMedCrossRef

Siddiqui FA, Lian EC (1993) Characterization of platelet agglutinating protein p37 purified from the plasma of a patient with thrombotic thrombocytopenic purpura. Biochem Mol Biol Int 30(2):385–395PubMed

10.

Praprotnik S, Blank M, Levy Y, Tavor S, Boffa MC, Weksler B, Eldor A, Shoenfeld Y (2001) Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 13(2):203–210PubMedCrossRef

11.

Schultz DR, Arnold PI, Jy W, Valant PA, Gruber J, Ahn YS, Mao FW, Mao WW, Horstman LL (1998) Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 103(3):849–857PubMedCrossRef

12.

Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J (1997) Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 89(4):1224–1234PubMed

13.

von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6(4):320–328CrossRef

14.

Amorosi EL, Ultmann JE (1966) Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 45:139–159

15.

Wyllie BF, Garg AX, Macnab J, Rock GA, Clark WF (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 132(2):204–209PubMedCrossRef

16.

Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325(6):393–397PubMedCrossRef

17.

Shumak KH, Rock GA, Nair RC (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 122(8):569–572PubMed

18.

Bell WR (1997) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning. Semin Hematol 34(2):134–139PubMed

19.

Ferrara F, Annunziata M, Pollio F, Palmieri S, Copia C, Mele G, Pocali B, Schiavone EM (2002) Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ann Hematol 81(1):7–10PubMedCrossRef

20.

Bobbio-Pallavicini E, Porta C, Centurioni R, Gugliotta L, Vianelli N, Tacconi F, Billio A, Ascari E (1994) Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP. Eur J Haematol 52(4):222–226PubMedCrossRef

21.

Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM (2007) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 136(1):146–149PubMedCrossRef

22.

Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM (2007) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 139(3):486–493PubMedCrossRef

23.

Agarwal V, Sharma BL, Aggarwal A, Misra R (2002) Does cyclophosphamide benefit relapsing thrombotic thrombocytopenic purpura? J Assoc Physicians India 50:1440–1442PubMed

24.

Hertzberg MS, Koutts J (1997) Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP). Aust N Z J Med 27(4):439PubMedCrossRef

25.

Zappasodi P, Corso A, Castagnola C, Tajana M, Lunghi M, Bernasconi C (1999) A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpura. Eur J Haematol 63(4):278–279PubMedCrossRef

26.

Moake JL, Rudy CK, Troll JH, Schafer AI, Weinstein MJ, Colannino NM, Hong SL (1985) Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 20(1):73–79PubMedCrossRef

27.

Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ (2003) Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 18(2):51–54PubMedCrossRef

28.

Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Lowenberg B, Brand A (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 130(5):768–776PubMedCrossRef

29.

Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP (2004) Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 77(2):171–176PubMedCrossRef

30.

Albaramki JH, Teo J, Alexander SI (2009) Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura. Pediatr Nephrol 24(9):1749–1752PubMedCrossRef

31.

Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, Sohngen D (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71(2):105–108PubMedCrossRef

32.

Chemnitz JM, Uener J, Hallek M, Scheid C (2010) Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 89(10):1029–1033PubMedCrossRef

33.

Dalia S, McNulty B, Colvin GA (2008) Rituximab in treating refractory thrombotic thrombocytopenic purpura: three case reports. Med Health R I 91(7):226–228PubMed

34.

Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC (2009) Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 83(4):365–372PubMedCrossRef

35.

Fakhouri F, Vernant J-P, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grunfeld J-P (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106(6):1932–1937PubMedCrossRef

36.

Gutterman LA, Kloster B, Tsai H-M (2002) Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 28(3):385–391PubMedCrossRef

37.

Koulova L, Alexandrescu D, Dutcher JP, O’Boyle KP, Eapen S, Wiernik PH (2005) Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 78(1):49–54PubMedCrossRef

38.

Ling HT, Field JJ, Blinder MA (2009) Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 84(7):418–421PubMedCrossRef

39.

Patino W, Sarode R (2007) Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis 22(1):17–20PubMedCrossRef

40.

Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC, Skikne BS, Sahud MA (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84(4):232–235PubMedCrossRef

41.

Sallah S, Husain A, Wan JY, Nguyen NP (2004) Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2(5):834–836PubMedCrossRef

42.

Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136(3):451–461PubMedCrossRef

43.

Lombardi AM, de Marinis GB, Scandellari R, Magalini F, Sansoni P, Ballerini PF, Vettore S, Candeo N, Marson P, De Silvestro G, Fabris F (2010) Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thromb Res 126(2):e154–e156PubMedCrossRef

44.

Basquiera AL, Damonte JC, Abichain P, Sturich AG, Garcia JJ (2008) Long-term remission in a patient with refractory thrombotic thrombocytopenic purpura treated with rituximab and plasma exchange. Ann Hematol 87(4):321–323PubMedCrossRef

45.

Hull MJ, Eichbaum QG (2006) Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 4(3):210–214 discussion 217–218PubMed

46.

Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C (2011) Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child. Pediatr Hematol Oncol 28(2):167–172PubMedCrossRef

47.

Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, Kuyama J (2005) Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 81(5):433–436PubMedCrossRef

48.

Mak SK, Lo KY, Lo MW, Chan SF, Lo KC, Wong YY, Tong GMW, Wong PN, Ma ESK, Wong AKM (2009) Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infection. Hong Kong Med 15(3):201–208

49.

Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, Brecher ME (2005) Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 45(9):1481–1486PubMedCrossRef

50.

Ojeda-Uribe M, Federici L, Wolf M, Coppo P, Veyradier A (2010) Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura [Erratum appears in Transfusion. 2010 May;50(5):1159]. Transfusion 50(3):733–735PubMedCrossRef

51.

Kuppachi S, Chander P, Yoo J (2009) Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab. J Nephrol 22(4):561–564PubMed

52.

Rufer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lammle B, Wuillemin WA (2007) Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly 137(37-38):518–524PubMed

53.

Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M (2004) Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 80(1):94–96PubMedCrossRef

54.

Tsai H-M, Shulman K (2003) Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 70(3):183–185PubMedCrossRef

55.

Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H-M (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124(6):787–795PubMedCrossRef

56.

Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab [Summary for patients in Ann Intern Med. 2003 Jan 21;138(2):I38; PMID: 12529111]. Ann Intern Med 138(2):105–108PubMed

57.

Darabi K, Berg AH (2006) Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 125(4):592–597PubMed

58.

Harambat J, Lamireau D, Delmas Y, Ryman A, Llanas B, Brissaud O (2011) Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. Pediatr Crit Care Med 12(2):e90–e93PubMedCrossRef

59.

Magalini F, Stella A, Basaglia M, Vescovini R, Sassi M, Maria Lombardi A, Sansoni P (2011) Thrombotic thrombocytopenic purpura with severe neurological impairment: remission after Rituximab. Transfus Med 21(2):140–143PubMedCrossRef

60.

Au W-Y, Ma ES, Lee T-L, Ha S-Y, Fung AT, Lie AKW, Kwong Y-L (2007) Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 137(5):475–478PubMedCrossRef

61.

Castagna L, Todisco E, Sarina B, Santoro A (2007) Rituximab in thrombotic microangiopathy. British J Haematol 139(1):166–167 author reply 166–167CrossRef

62.

Carella AM, D’Arena G, Greco MM, Nobile M, Cascavilla N (2008) Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transpl 41(12):1063–1065CrossRef

63.

Evans MW, Vaughan LB, Giffi VS, Zimrin AB, Hess JR (2010) Rituximab treatment for thrombotic thrombocytopenic purpura associated with human immunodeficiency virus failing extensive treatment with plasma exchange: a report of two cases. AIDS Patient Care STDS 24(6):349–352PubMedCrossRef

64.

Kameda T, Dobashi H, Kittaka K, Susaki K, Yamaoka G, Arai K, Tokuda M, Ishida T (2007) Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol 26(12):2159–2162PubMedCrossRef

65.

Asamiya Y, Moriyama T, Takano M, Iwasaki C, Kimura K, Ando Y, Aoki A, Kikuchi K, Takei T, Uchida K, Nitta K (2010) Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis. Intern Med 49(15):1587–1591PubMedCrossRef

66.

Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, Marone C, Cavalli F (2006) Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 77(6):527–529PubMedCrossRef

67.

Gourley BL, Mesa H, Gupta P (2010) Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemother Pharmacol 65(5):1001–1004PubMedCrossRef

68.

Gupta D, Roppelt H, Bowers B, Kunz D, Natarajan M, Gruber B (2008) Successful remission of thrombotic thrombocytopenic purpura with rituximab in a patient with undifferentiated connective tissue disorder. J Clin Rheumatol 14(2):94–96PubMedCrossRef

69.

Halim AG, Soehardy Z, Shahrir, Rozita M, Loo CY, Rashidi S, Norella Kong CT (2008) Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus. Int J Rheum Dis 11(1):69–72CrossRef

70.

Hong MJ, Lee HG, Hur M, Kim SY, Cho YH, Yoon SY (2011) Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment. Korean J Hematol 46(1):45–48PubMedCrossRef

71.

Hundae A, Peskoe S, Grimsley E, Patel S (2008) Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J 101(9):943–944PubMedCrossRef

72.

Kamiya K, Kurasawa K, Arai S, Maezawa R, Hanaoka R, Kumano K, Fukuda T (2010) Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 20(1):81–85PubMedCrossRef

73.

Limal N, Cacoub P, Sene D, Guichard I, Piette JC (2008) Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 17(1):69–71PubMedCrossRef

74.

Niaz FA, Aleem A (2010) Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl 21(1):109–112PubMed

75.

Onitilo AA, Engel JM, Clouse LH, Gerndt KM (2009) Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. J Vasc Interv Radiol 20(2):275–276PubMedCrossRef

76.

Pieringer H, Schmekal B, Gruber F, Vosko MR, Biesenbach G (2009) Transient hemolytic anemia after kidney transplantation and thrombotic thrombocytopenic purpura refractory to plasma exchange and rituximab. Ren Fail 31(5):419–420PubMedCrossRef

77.

Ross CL, Hunt BJ, Wyncoll D, Hodgkiss A, Peters B (2009) HIV, thrombotic thrombocytopaenic purpura and rituximab in a violent noncompliant patient. Blood Coagul Fibrinolysis 20(2):157–160PubMedCrossRef

78.

Ruiz J, Koduri PR, Valdivieso M, Shah PC (2005) Refractory post-pancreatitis thrombotic thrombocytopenic purpura: response to rituximab. Ann Hematol 84(4):267–268PubMedCrossRef

79.

Benetatos L, Vassou A, Bourantas KL (2006) Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura. Clin Lab Haematol 28(4):288–289PubMedCrossRef

80.

Tripodi A, Chantarangkul V, Bohm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM (2004) Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2(9):1601–1609. doi:10.1111/j.1538-7836.2004.00879.x PubMedCrossRef

81.

Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102(9):3241–3243PubMedCrossRef

82.

Shelat SG, Smith P, Ai J, Zheng XL (2006) Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 4(8):1707–1717PubMedCrossRef

83.

Rose M, Eldor A (1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 83(3):437–444PubMedCrossRef

84.

Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M (2007) A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. J Thromb Thrombolysis 23(2):147–150PubMedCrossRef

Title: Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis
Authors: Nay M. Tun
Gina M. Villani
Publication date: 01-10-2012
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-012-0723-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy

Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura

Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT

Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers

A case of IVC filter thrombosis

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials